Patent intelligence · CA
CA 3169263
AGENTS DE TRAITEMENT DE MALADIES CANCEREUSES EXPRIMANT CLAUDINE
AGENTS DE TRAITEMENT DE MALADIES CANCEREUSES EXPRIMANT CLAUDINE
Patent details — CA 3169263
- Jurisdiction
- CA
- Status
- granted
- Grant date
- May 22, 2014
- Expiration
- May 17, 2034
- Applicant
- TRON TRANSLATIONALALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GEMENNUTZIGE GMBH [DE]
- CPC classes
- A61K/3939558, A61P/3500, A61P/3504
Quick answer
CA 3169263 (AGENTS DE TRAITEMENT DE MALADIES CANCEREUSES EXPRIMANT CLAUDINE) is held by TRON TRANSLATIONALALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GEMENNUTZIGE GMBH [DE]. Status: granted. Granted May 22, 2014. Expires May 17, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TRON TRANSLATIONALALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GEMENNUTZIGE GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/3939558, A61P/3500, A61P/3504
More from TRON TRANSLATIONALALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GEMENNUTZIGE GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 3169263?
CA 3169263 (AGENTS DE TRAITEMENT DE MALADIES CANCEREUSES EXPRIMANT CLAUDINE) is held by TRON TRANSLATIONALALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GEMENNUTZIGE GMBH [DE]. Status: granted. Granted May 22, 2014. Expires May 17, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3169263?
TRON TRANSLATIONALALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GEMENNUTZIGE GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3169263 expire?
Our index shows an expiration date of May 17, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.